RB’s attempt to monopolize the extended-release guaifenesin OTC category thwarted Mutual PharmaceuticalCo. Inc.’splan to market an “authorized generic” of extended-release Mucinex, according to an antitrust complaint.
Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin
Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.